Storia in 9 fonti

200% Trump tariff shock? India’s cheap pills may still beat US rivals

US President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical exporters, but the country's cost advantage may help many drugs remain competitive in the US market, according to the Global Trade Research Initiative (GTRI).

Raccontata da

timesofindia.indiatimes.com

hindustantimes.com

economictimes.indiatimes.com

newsbytesapp.com

thehindubusinessline.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

economictimes.indiatimes.comStai leggendo1 mese fa

200% Trump tariff shock? India’s cheap pills may still beat US rivals

originale

Timeline cronologica

mercoledì 22 luglio 2026·timesofindia.indiatimes.com
Trump announces 0% tariff on generic medicines for two years; 200% thereafter
US President Donald Trump on Tuesday announced a phased tariff regime on imported generic medicines, saying they will continue to enter the United States duty-free for two years…
mercoledì 22 luglio 2026·hindustantimes.com
0% for two years, 100% for one, 200 after: US' latest tariff move over generic medicines
In 2025, India exported USD 9.7 billion worth of pharmaceuticals to the US, accounting for 38 per cent of its total global pharma exports of USD 25.8 billion. | India News

200% Trump tariff shock? India’s cheap pills may still beat US rivals

Confronto fonti

200% Trump tariff shock? India’s cheap pills may still beat US rivals

Timeline cronologica

Trump announces 0% tariff on generic medicines for two years; 200% thereafter

0% for two years, 100% for one, 200 after: US' latest tariff move over generic medicines

Donald Trump’s 200% tariffs on pharma: Why India’s generic medicines could still remain competitive

0, 100, 200: How Trump's latest generic medicines tariffs could affect India

Trump threatens tariff on generic medicines: Should India be worried?

Trump's generic drugs tariff threatens Indian pharma's top market

US proposal to impose steep tariffs on generic medicines could significantly impact India: GTRI

Sun Pharma, Cipla, other pharma stocks in focus as Trump unveils 100%, 200% tariffs on generic drugs from 2028

0%, 100%, then 200%: How Trump's new generic drug tariff plan could hit India

Trump threatens tariff on generic medicines: Should India be worried?

0, 100, 200: How Trump's latest generic medicines tariffs could affect India

Trump’s proposed generic drug tariffs ‘not practical’, says Indian pharma; US consumers will pay the price

0% now, 100% in 2 years, 200% by 2029—US plan for generic pharma tariffs & what it means for India

Pharma stocks bleed after Trump announces up to 200% tariff on generic drugs; Aurobindo, Sun Pharma & Cipla slide over 3%

Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% storm

Trump's 200% drug tariff plan: Is India's pharma industry about to face an economic storm?

Trump’s 100% generic drug duty threatens US low-cost supply

200% Trump tariff shock? India’s cheap pills may still beat US rivals

Indian pharma firms may yet survive Trump's 200% tariff bombshell

Explained: What Donald Trump's up to 200% pharma tariffs mean for Indian investors

Donald Trump’s 200% tariffs on pharma: Why India’s generic medicines could still remain competitive

Trump announces plan for 200% tariffs on imported generic drugs

US proposal to impose steep tariffs on generic medicines could significantly impact India: GTRI

Trump's generic drugs tariff threatens Indian pharma's top market

What would 200% US tariffs on generic drugs mean for China’s pharmaceutical industry?